HomeCompareIOBCF vs ARCC

IOBCF vs ARCC: Dividend Comparison 2026

IOBCF yields 1.84% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IOBCF wins by $45.32M in total portfolio value· pulled ahead in Year 3
10 years
IOBCF
IOBCF
● Live price
1.84%
Share price
$15.00
Annual div
$0.28
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.35M
Annual income
$41,068,608.41
Full IOBCF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — IOBCF vs ARCC

📍 IOBCF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIOBCFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IOBCF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IOBCF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IOBCF
Annual income on $10K today (after 15% tax)
$156.68/yr
After 10yr DRIP, annual income (after tax)
$34,908,317.15/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, IOBCF beats the other by $34,908,316.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IOBCF + ARCC for your $10,000?

IOBCF: 50%ARCC: 50%
100% ARCC50/50100% IOBCF
Portfolio after 10yr
$22.69M
Annual income
$20,534,304.79/yr
Blended yield
90.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

IOBCF
No analyst data
Altman Z
2.4
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IOBCF buys
0
ARCC buys
0
No recent congressional trades found for IOBCF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIOBCFARCC
Forward yield1.84%10.82%
Annual dividend / share$0.28$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%-50%
Portfolio after 10y$45.35M$24.5K
Annual income after 10y$41,068,608.41$1.16
Total dividends collected$44.99M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: IOBCF vs ARCC ($10,000, DRIP)

YearIOBCF PortfolioIOBCF Income/yrARCC PortfolioARCC Income/yrGap
1$11,069$368.67$11,381$541.15$312.00ARCC
2$12,606$762.74$12,621$284.08$15.00ARCC
3← crossover$15,112$1,623.72$13,827$145.31+$1.3KIOBCF
4$19,809$3,638.35$15,062$73.43+$4.7KIOBCF
5$30,109$8,913.99$16,364$36.89+$13.7KIOBCF
6$57,543$25,325.84$17,757$18.49+$39.8KIOBCF
7$152,040$90,469.27$19,258$9.25+$132.8KIOBCF
8$609,485$446,801.92$20,880$4.63+$588.6KIOBCF
9$4,000,001$3,347,852.94$22,636$2.32+$3.98MIOBCF
10$45,348,610$41,068,608.41$24,539$1.16+$45.32MIOBCF

IOBCF vs ARCC: Complete Analysis 2026

IOBCFStock

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Full IOBCF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this IOBCF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IOBCF vs SCHDIOBCF vs JEPIIOBCF vs OIOBCF vs KOIOBCF vs MAINIOBCF vs HTGCIOBCF vs GBDCIOBCF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.